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Abstract
Regardless of the achievable remissions with first line hormone therapy in patients with prostate cancer (CaP), the disease
escapes the hormone dependent stage to a more aggressive status where chemotherapy is the only effective treatment and
no treatment is curative. This makes it very important to identify new targets that can improve the outcome of treatment.
ATM and DNA-PK are the two kinases responsible for signalling and repairing double strand breaks (DSB). Thus, both kinases
are pertinent targets in CaP treatment to enhance the activity of the numerous DNA DSB inducing agents used in CaP
treatment such as ionizing radiation (IR). Colony formation assay was used to assess the sensitivity of hormone dependent,
p53 wt (LNCaP) and hormone independent p53 mutant (PC3) CaP cell lines to the cytotoxic effect of IR and Doxorubicin in
the presence or absence of Ku55933 and NU7441 which are small molecule inhibitors of ATM and DNA-PK, respectively.
Flow cytometry based methods were used to assess the effect of the two inhibitors on cell cycle, apoptosis and H2AX foci
formation. Neutral comet assay was used to assess the induction of DNA DSBs. Ku55933 or NU7441 alone increased the
sensitivity of CaP cell lines to the DNA damaging agents, however combining both inhibitors together resulted in further
enhancement of sensitivity. The cell cycle profile of both cell lines was altered with increased cell death, DNA DSBs and
H2AX foci formation. This study justifies further evaluation of the ATM and DNA-PK inhibitors for clinical application in CaP
patients. Additionally, the augmented effect resulting from combining both inhibitors may have a significant implication for
the treatment of CaP patients who have a defect in one of the two DSB repair pathways.
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Introduction
According to the U.S National Institutes of Health, the age-
adjusted incidence rate of prostate cancer 2003–2007 was 156.9 per
100.000 men per year. Although high response rates can be
achieved by first line therapy with surgery, radiotherapy, antian-
drogen or their combinations; the natural progress of the disease is
towards the hormone refractory status [1] where chemotherapy is
the most effective treatment but still not curative [2]. This resistance
highlights the importance of identifying new targets that can
increase the sensitivity of CaP cells and hence the response rates and
overall survival of patients. Ataxia telangiectasia mutated (ATM)
and the DNA dependent protein kinase catalytic subunit (DNA-
PKcs) are members of the phosphatidyl inositol 3-kinase related
kinases (PIKK) superfamily. Members of this family are char-
acterised by their high molecular weight and sequence similarity to
the p110 subunit lipid kinase PI3-kinase [3]. In mammalian cells,
ATM and DNA-PK play key roles in the DNA double strand break
(DSB) response, via homologous recombination (HR) and non
homologous end joining (NHEJ), respectively [4,5]. Rapid phos-
phorylation of both ATM and DNA-PK occurs in response to DSB
following endogenous or exogenous insults. Once activated, ATM
and DNA-PK signal to a wide spectrum of downstream targets that
are involved in the repair process, cell cycle regulation and apoptosis
[6]. The choice of which pathway repairs the DSB is cell cycle stage
dependent, with NHEJ being the dominant pathway in G0 and G1,
and HR dominates in S and G2/M phases [7]. ATM and DNA-PK
are cleaved by caspase 3 once the decision to activate apoptosis is
made in the cell and this cleavage event is thought to facilitate
apoptosis by disabling the DNA signalling and repair machinery
[8,9]. Traditional PI3K inhibitor, wortmannin with generally low
selectivity against different classes and/or isoforms of PIKK has
been widely used to study ATM and DNA-PK signalling pathways
[10]. Ku55933 was identified as a potent and specific ATP
competitive inhibitor of ATM (IC50 13 nmol/L) with respect to
the inhibition of other members of the PIKK family. Ku55933
increased the sensitivity of breast cancer cells to IR, altered their cell
cycle profile, and inhibited the phosphorylation of a panel of ATM
targets. A–T cells did not show these effects when treated with
Ku55933 [11]. NU7441 was identified as a potent and specific ATP
competitive inhibitor of DNA-PK (IC50 14 nmol/L) with 100-fold
selectivity for DNA-PK relative to other members of the PI3KK
family. NU7441 increased the sensitivity of colon cancer cells to IR
and topoisomerase II inhibitors, and altered their cell cycle profile.
DNA-PK deficient V3 cells did not show these effects when treated
with NU7441 [12]. This study was designed as a preclinical
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evaluation of both ATM and DNA-PK inhibitors to investigate
whether these inhibitors can improve the efficacy of DNA DSB
inducing agents for CaP treatment.
Materials and Methods
Chemicals
All routine chemicals were purchase from Sigma unless
otherwise stated. NU7441 was synthesised at the Northern
Institute for Cancer Research, Newcastle University (Newcastle
upon Tyne, UK) in collaboration with KuDOS Pharmaceuticals
(Cambridge, UK). KU-55933 was a kind gift from KuDOS
Pharmaceuticals. Both inhibitors were dissolved in DMSO at a
stock concentration of 20006 the final concentration required for
the experiment. Doxorubicin was dissolved in water at stock
concentration of 10006 the final concentration required for the
experiment. All compounds were stored in aliquots at 220uC.
Cell culture
LNCaP hormone sensitive (p53 wild type) and PC3 hormone
insensitive (p53 null) CaP cell lines were purchased from ATCC
and cultured in RPMI 1640 medium supplemented with 10% (v/
v) FCS. Both cell lines were routinely screened for Mycoplasma.
Colony formation assay
Cells were seeded in 6 well plates at different densities. After
allowing to attach, cells were incubated with Ku55933 (10 mM)
alone or in combination with NU7441 (1 mM) for 1 h before either
irradiation (0–2 Gy) or doxorubicin treatment (0–75 nM). 24 h
later, wells were gently washed twice with warm PBS before adding
fresh medium and returned to the incubator for 7–10 days for PC3
cells and 12–14 days for LNCaP cells to form colonies. Colonies
were fixed with Carnoy fixative, dried, stained with 0.4% crystal
violet and counted manually. The survival reduction factor was
calculated as the surviving fraction of cells in the absence of the
inhibitors divided by the surviving fraction of cells in the presence of
inhibitors for any given dose or concentration of cytotoxic agent.
Flow cytometry based method for cell cycle
Cells were seeded in 6 well plates. 24 h later, cells were treated
with 1 mM NU7441 and/or 10 mM Ku55933 prior to IR or
doxorubicin treatment. 48 h later, cells were collected in FACS
tubes (Becton & Dickinson, Oxford UK) maintaining the growth
medium before being stained with propidium iodide (PI). Samples
were analyzed directly on a FACScan (Becton & Dickinson),
fluorescence intensity in arbitrary units was plotted in histograms,
and the cell cycle phases were determined using WINMDI version
2.8 (The Scrrips Research Institute, USA).
Flow cytometry based method for active caspase 3
Cells were seeded in 6 well plates and treated with the inhibitors
and/or DNA damaging agent as previously described and
collected in FACS tubes maintaining the growth medium. Cells
were stained with FITC conjugated active caspase 3 antibody
according to the manufacturer’s instructions (Becton Dickinson,
Oxford UK) and analyzed directly on a FACScan. Fluorescence
intensity in arbitrary units was plotted in dot plots, and the mean
fluorescence intensity was calculated using WINMDI version2.8.
Flow cytometry based method for c-H2AX foci formation
Cells were seeded in 6 well plates, treated with the inhibitors
and/or DNA damaging agent as previously described and
collected in FACS tubes. Cells were stained using FITC
conjugated cH2AX antibody as described previously [13].
Samples were analyzed directly on a FACScan. Fluorescence
intensity in arbitrary units was plotted in histograms, and the mean
fluorescence intensity was calculated using WINMDI version2.8.
Western blotting
Whole cell extracts were prepared 6 h after 1 mM doxorubicin
and 1 h after 10 Gy IR in the presence and absence of the inhibitors.
Equivalent amounts of cell lysate were loaded onto 4.5, 6, 12 and
15% gels alongside a protein marker SeeBlueH Pre-Stained Standard
(Invitrogen, USA). Gels were electrophoresed and proteins were
transferred to Hybond-C membrane. ECL-system (GE Healthcare,
Buckinghamshire, UK) was used to detect antibody conjugated
proteins according to the manufacturer’s instructions and visualised
by exposure to X-ray film (Kodak, Herts, UK). Anti DNA-PK, anti
ATM, anti DNA-PK Ser2056 and anti DNA-PKThr2906 were
purchased from (Abcam, Cambridge UK). Anti ATMSer1981, anti
H2AXSer139 and anti p53Ser15 were purchased from (Gene Tex,
USA), (Upstate, UK) and (Cell signalling, UK), respectively.
Neutral comet assay
PC3 were subjected to the neutral comet assay according to the
manufacturer instructions (Trevigen, Inc., Gaithersburg, MD,
USA). Two main modifications were applied, the cells were lysed
for 1 h and electrophoresed for 30 minutes at 30 V. Comets were
visualized by fluorescence Leica DMR microscope and analyzed
using Komet 5.5 (kinetic imaging Ltd, Nottingham, UK).
Statistical analysis
Statistical analysis was applied using prism software version4
(GraphPad Prism, San Diego, USA).
Results
Ku55933 and NU7441 inhibit ATM and DNA-PK kinase
activity respectively in IR and doxorubicin treated CaP
cells
ATM-dependent ATMSer1981, p53Ser15, H2AXSer139 and DNA-
PKThr2609 phosphorylation were induced 1 h after 10 Gy and 6 h
after 1 mMdoxorubicin and were inhibited by Ku55933. IR induced
DNA-PKSer2056 phosphorylation (reported as DNA-PK autopho-
sphorylation site) was inhibited by NU7441 (as expected) and
surprisingly doxorubicin induced DNA-PKSer2056 phosphoryla
tion was also inhibited by Ku55933. NU7441 did not inhibit
ATMSer1981, p53Ser15, H2AXSer139 and DNA-PKThr2609 phosphor-
ylation (Figure 1).
Ku55933 and NU7441 are minimally cytotoxic to CaP cells
In order to determine the intrinsic cytotoxicity of Ku55933 and
NU7441 in relation to chemo and radiosensitization, cells were
exposed to increasing concentrations of Ku55933 or NU7441 with
minimally cytotoxic concentration of IR (1 Gy) or doxorubicin
(10 nM). Both Ku55933 (10 mM) and NU7441 (1 mM) caused
minimal or no cytotoxicity in LNCaP (Figure 2A&B) and PC3
(Figure 2C&D). Each inhibitor significantly increased IR and
doxorubicin cytotoxicity in both CaP cell lines in an inhibitor
dose-dependent manner. These two concentrations (10 mM
Ku55933 or 1 mM NU7441) were used in subsequent experiments.
Ku55933 and NU7441 reduced CaP cell lines cellular
survival in response to IR or doxorubicin
Having demonstrated a concentration-dependent chemo and
radiosensitization in both cell lines, we then investigated the
DNA Double Strand Break Repair in Prostate Cancer
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response to a fixed concentration of each inhibitor with increased
concentrations of doxorubicin or IR dose. There was a dose
dependent decrease in cell survival in response to IR. PC3 cells
displayed resistance to IR compared to LNCaP, combining
NU7441 or Ku55933 with IR significantly reduced the cell
survival for LNCaP (Figure 2E) and substantially for PC3
(Figure 2G). Similarly, doxorubicin reduced cell survival in both
cell lines, Further chemo-sensitization resulted from combining
NU7441 or Ku55933 in LNCaP (Figure 2F) and PC3 (Figure 2H).
Combining both inhibitors significantly increased the chemo-
radiosensitization and NU7441 combination was more effective in
inducing chemosensitisation in LNCaP whereas Ku55933 combi-
nation had more effect in inducing radiosensitization in PC3
suggesting an advanced role for ATM in the hormone refractory
model.
Ku55933 and NU7441 altered cell cycle and increased
their apoptosis in response to DNA damage in CaP cell
lines
We next determined whether the increased sensitivity of CaP
cell lines is accompanied by increased apoptosis or changes in the
cell cycle profile. IR caused minimal/no increase in LNCaP
(Figure 3A) compared to a dose-dependent increase in G2
accumulation in PC3 (Figure 3B). Additionally, the combination
of both inhibitors had an additive effect on the G2 accumulation at
low dose (2 Gy) but not at high dose (10 Gy). Doxorubicin
treatment caused cells to accumulate in G2/M especially at high
dose. In general, combining either inhibitor with a low dose
doxorubicin (20 nM) increased G2/M accumulation although
NU7441 had only modest effect in LNCaP cells (Figure 3C).
Whereas the single inhibitor combination at high dose doxorubicin
(200 nM) resulted in a striking increase in subG1 in LNCaP
(Figure 3C) compared to an interesting increase in G1 in PC3 cells
(Figure 3D). An additive effect was observed when combining both
inhibitors.
IR induced a dose dependent cell death in both cell lines.
LNCaP apoptosis was enhanced when combining Ku55933 and/
or NU7441 (Figure 3E). However, PC3 cell death (Figure 3F) was
increased in response to the inhibitor combinations at low dose
only. The increased apoptosis caused by the combination of both
inhibitors is consistent with the survival data showing radio-
sensitisation was more pronounced for both cell lines treated with
both inhibitors together. Additionally, Ku55933 induced greater
cell death in PC3 cells compared to NU7441 which was a
consistently observed effect of Ku55933 on the survival of
irradiated PC3 cells. Doxorubicin caused a dose-dependent
increase in caspase 3 activity in both cell lines. Combining
Ku55933 and/or NU7441 with 20 nM doxorubicin enhanced the
cell death of LNCaP (Figure 3E) and PC3 (Figure 3F) cells. A
massive increase in LNCaP apoptosis resulted from Ku55933
and/or NU7441 combined with 200 nM doxorubicin, 95–99% of
cells were positive for active caspase3, whereas no increase was
detected in PC3 under the same conditions.
Finally, the apoptosis data is consistent with survival data as the
massive induction of apoptosis correlates with severe reduction in
the cellular survival at high doses of doxorubicin. Furthermore,
NU7441 was superior to the Ku55933 in inducing apoptosis in
LNCaP cells. Whereas, Ku55933 had greater effect in PC3 cells
which is consistent with the survival data.
Ku55933 and NU7441 increase the induction of DNA DSB
in CaP cell lines
We investigated whether the increase in CaP cell lines
sensitivity in response to ATM and/or DNA-PK inhibition is a
result of increased number of DNA DSBs by a direct measure of
H2AX signal and a direct measure of DNA DSB (neutral comet
assay). As anticipated c-H2AX signal increased 0.5 h following
IR in both cell lines and returned to normal levels within 4 h in
LNCaP cells (Figure 4A) whereas it was only reduced by 50% in
PC3 cells (Figure 4B) which suggest greater repair capacity in
LNCaP compared to PC3. Doxorubicin treatment caused time-
dependent increase in c-H2AX in LNCaP (Figure 4C) and PC3
(Figure 4D). Combining either Ku55933 or both inhibitors with
either IR or doxorubicin reduced the c-H2AX signal in both cell
lines at all time points examined which is consistent with ATM
being the major kinase responsible for H2AX phosphorylation
and the inability of DNA-PK to phosphorylate H2AX in the
presence of inhibited ATM. NU7441 modestly inhibited the
initial c-H2AX induction in both cell lines following IR and
doxorubicin. However, at later time points inhibiting DNA-PK
resulted in increased c-H2AX signal reflecting increased DNA
DSBs highlighted by c-H2AX, a consequence of phosphoryla-
tion by the active ATM. Noteworthy, in experiments where both
kinases were inhibited there was no further increase in H2AX
signal. PC3 cells showed a small increase in the comet tail
moment 24 h following IR or doxorubicin reflecting their high
capability to repair their DNA damage lesions. However,
combining either inhibitor with either DNA damaging agent
caused modest increase in the tail moment. Combining both
inhibitors had an additive increase in the tail moment
(Figure 4E).
Noteworthy, the increase resulting from the doxorubicin
treatment was higher compared to that resulting from IR; this
could be in part related to the fact that IR mainly induces higher
level of single strand breaks.
Figure 1. Ku55933 and NU7441 inhibit ATM and DNA-PK,
respectively.Whole LNCaP cell extracts were prepared 1 h after 10 Gy
and 6 h after 1 mM doxorubicin 610 mM Ku55933 or 1 mM NU7441.
Extracts were analyzed by western blotting and probed with the
indicated antibodies. Data is a representative of three independent
experiments.
doi:10.1371/journal.pone.0020311.g001
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Discussion
Ku55933 and NU7441 are potent inhibitors of ATM and
DNA-PK, respectively. Each inhibitor abolished the autopho-
sphorylation of its own protein target in both CaP cell lines
following IR. The data with doxorubicin treatment was similar
between the two cell lines but the phosphorylation of DNA-
PKSer2056 appears not to be inhibited by NU7441. Notably, the
phosphorylation of the downstream targets H2AXSer139 and
p53Ser15 which are mainly regulated by ATM was abolished
when both inhibitors were combined. Furthermore, a novel
phosphorylation event is reported here as the phosphorylation of
Ser2056 of DNA-PKcs, believed to be a true autophosphoryla-
tion site for DNA-PK [14], was reduced following Ku55933
treatment (not NU7441) in response to doxorubicin but not IR
treatment suggesting this site could be targeted by ATM,
depending on the DNA damage inducing agent. A relevant
control would be to deplete native ATM and substitute it with a
kinase-dead ATM.
Combining either inhibitor with IR or doxorubicin resulted in a
massive and significant increase in the sensitivity of LNCaP and
PC3 cells to the cytotoxic effect of both IR and doxorubicin.
Additionally, combining the two inhibitors together with DNA
damaging agents resulted in further enhancement in the
cytotoxicity compared to single inhibitor combination. This
concurs with reported literature where targeting ATM and
DNA-PK using siRNA methodology revealed increased sensitivity
to IR and to chemotherapy in different CaP cell lines [15]. The
increased sensitivity resulting from the combination of both
inhibitors could have a significant implication for the treatment
of CaP in patients with a defect in the HR or NHEJ pathways such
as BRCA mutation carriers [16]. Patients with defect in one repair
pathway could potentially be treated with the inhibitor of the other
pathway and benefit from maximum treatment outcome with
minimal toxicity.
Herein, a major characteristic of the PC3 cell cycle, lack of p53
function, led to an increased accumulation in the G2/M phase of
the cell cycle in the presence of ATM, DNA-PK or both inhibitors
Figure 2. Ku55933 and/or NU7441 sensitised CaP cells to IR or doxorubicin. LNCaP (A&B) or PC3 (C&D) cells were seeded in different
densities and left to attach before 1 h incubation with varying concentration of Ku55933 or NU7441 prior to irradiation 1 Gy or 10 nM doxorubicin
treatment for 24 h (P,0.001). LNCaP (E&F) or PC3 (G&H) cells were seeded in different densities and left to attach before 1 h incubation with
Ku55933 (10 mM) or NU7441 (1 mM) prior to treatment with varying IR doses or doxorubicin concentration for 24 h (P,0.001). All results are the mean
of three independent experiments 6 SEM.
doi:10.1371/journal.pone.0020311.g002
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particularly when combined with IR treatment. However,
inhibiting either ATM or DNA-PK or both in combination with
high dose doxorubicin treatment increased the G1-phase accu-
mulation, suggesting activation of the G1 checkpoint by other
pathways such as the p38MAPK/MK2 [17]. In the presence of
functional p53 (LNCaP cells), cells accumulated in G2/M-phase
when ATM was inhibited while they accumulated in G1 when
DNA-PK was inhibited. This could explain the survival data since
the accumulation in G2 would allow more NHEJ mediated DNA
repair. This data supports previous reports suggesting that the
effect of DNA-PK on p53 contributes to the apoptosis process
rather than to cell cycle control. It is interesting that ATM
inhibition leads to G2 accumulation which may be explained by
the effect of kinase active ATR in the absence of active ATM
kinase [18]. Interestingly, combining either inhibitor or the dual
inhibitor combination with high dose doxorubicin (excessive DNA
damage) resulted in a dramatic increase in the subG1 population,
an indication of apoptosis. This suggests that the presence of p53
can trigger cell death when the damage in DNA is too substantive
to be repaired. Our data is consistent with a role for ATM and
DNA-PK in cell cycle regulation through their effect on different
proteins [19].
In this study, the effect of inhibiting ATM or DNA-PK on the
cellular death of CaP cell lines revealed that, independent of p53
status or the hormone dependency, this inhibition increased the
programmed cell death induced by low doses of either doxorubicin
or IR. However, the presence of p53 (LNCaP cells) greatly
increased the apoptotic population with high dose doxorubicin.
Whereas, in the absence of p53 (PC3 cells) there was either none
or a small increase in cell death with high dose doxorubicin which
is consistent with observed increase in cell cycle arrest. The more
pronounced apoptosis in PC3 compared to LNCaP at low doses of
DNA damage could be explained by the shorter period of
treatment (48 h) for LNCaP compared to (96 h) for PC3 cells.
We observed that the primary induction of H2AX foci was
substantially reduced by combining either or both inhibitors with
DNA damaging agents. At later time points, H2AX foci formation
were still inhibited in the ATM inhibitor combination arms,
whereas it increased in the DNA-PK inhibitor arms. This implies
that DNA-PK inhibition increases the DNA DSBs that are
highlighted by increased number of H2AX foci formed at the
damage site. However, decreased H2AX foci formation in the
ATM inhibitor arms is not a consequence of less DSBs being
generated as we demonstrated increased DNA DSBs using the
Figure 3. Ku55933 and NU7441 altered CaP cell lines cell cycle and increased apoptosis. LNCaP (A&C) and PC3 (B&D) cells were
incubated with Ku55933 (10 mM) and/or NU7441 (1 mM) before being exposed to the indicated doses of IR or doxorubicin for 48 h and then stained
with PI and analysed directly on FACscan. Data is a representative three independent experiments. LNCaP (E) and PC3 (F) cells were treated as
described above and stained with FITC-conjugated anti caspase 3 antibody before direct analysis on FACScan. Results are the mean of three
independent experiments 6 SD.
doi:10.1371/journal.pone.0020311.g003
DNA Double Strand Break Repair in Prostate Cancer
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20311
neutral comet assay. This is consistent with the data suggesting
that ATM is the major kinase that induces H2AX foci and that
DNA-PK can phosphorylate H2AX only in the absence of ATM
but not in the presence of chemically inhibited ATM [20]. This
data is consistent with a report using other methods for H2AX
detection [21] where the initial H2AX foci formation (30 min
following IR) was abolished when combining ATM and/or DNA-
PK inhibitors. Another report contradicts with our data [22]
where they demonstrated DNA-PK plays dominant role in H2AX
foci formation in the absence of ATM function; however this
report used cell lines that lack either ATM or DNA-PK which is
not the case in our cell lines. Additionally, inhibiting both ATM
and DNA-PK did not result in increased H2AX signal at all time
points. This suggests that ATR (the third kinase implicated in
H2AX phosphorylation) is unable to carry out this phosphoryla-
tion function in the presence of ATM and DNA-PK even when
both are inhibited. An interesting approach would be to
investigate the effect on Rad51 foci formation when these kinases
are inhibited.
The key role of ATM and DNA-PK in repairing DNA DSB in
mammalian cells suggests that knocking down the function of
either or both proteins should increase the numbers of DNA DSBs
following an inducing treatment. Using the neutral comet assay we
showed that inhibition of ATM and/or DNA-PK resulted in
increased number of DNA DSBs following IR or doxorubicin
treatment. An additive effect was observed in the treatment arms
where both kinases were inhibited. It is interesting that the comet
tails are almost equal in the single inhibitor arms although it would
be expected that the DNA-PK inhibitor should cause more
increase in DSBs as NHEJ is the major pathway for repairing
DNA DSBs. This may be because we conducted the comet assay
at 24h, which is more physiologically meaningful to the cells but
does not necessarily reflect the repair kinetics. Most DSBs are
repaired rapidly by NHEJ and then slower kinetics by HR for
residual frank DSBs and DSBs resulting from stalled replication
fork. ATM impacts on HR therefore KU55933 should diminish
this slow phase even further and therefore a greater number of
breaks at 24 hr compared to when HR is not inhibited (control
and DNA-PK inhibitor arms).
In summary, this study reports a novel treatment for prostate
cancer by targeting the DNA DSBs repair machinery. We show
that targeting DSB repair confers an enhanced chemo- and radio-
sensitivity in hormone sensitive and insensitive CaP cell lines
associated with increased programmed cell death. Further
Figure 4. Ku55933 and NU7441 increased DNA DSB in CaP cell lines. LNCaP (A&C) and PC3 (B&D) cells were treated with 10 Gy or 1 mM
doxorubicin following 1 h incubation with Ku55933 (10 mM) and/or NU7441 (1 mM) and stained with FITC-conjugated H2AX antibody before being
analysed directly on FACscan. Results are the mean of at least 5 independent experiments6SEM. PC3 (E) cells were treated as above for 24 h and
analysed using comet assay, 50 cells were counted per arm treatment. Results are the mean of 3 independent experiments 6 SEM.
doi:10.1371/journal.pone.0020311.g004
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evaluation of the specific inhibitors needs to be conducted in
animal models, including the assessment of plasma availability,
toxicity, and efficacy before moving further towards any clinical
trial.
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